Riviciclib hydrochloride (P276-00) is a novel inhibitor of CDK1, CDK4, and CDK9 with IC50 of 79 nM, 63 nM, and 20 nM, respectively. Riviciclib hydrochloride (P276-00) can induce apoptosis. Phase 2/3.

Brand: BCM

 

Target: Apoptosis; CDK

 

Signaling Pathways: Cell Cycle/Checkpoint; Apoptosis

 

Solubility: Soluble in DMSO; soluble in Water; soluble in Ethanol.

 

Isomeric SMILES: CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl  

 

InChIKey: OOVTUOCTLAERQD-OJMBIDBESA-N  

 

InChI: InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1

 

Attribute
[CAS No.]	920113-03-7
[Formula]	C21H20ClNO5.HCl
[Molecular]	438.3
[Chem Name]	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
[Synonym]	P276-00; Riviciclib hydrochloride
[Storage]	Store at -20° C
[MDL No.]	MFCD26960898

Goods Tag